1
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: state
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Yan K, Gao J, Yang T, et al: MicroRNA-34a
inhibits the proliferation and metastasis of osteosarcoma cells
both in vitro and in vivo. PLoS One. 7:e337782012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Jin Y, Peng D, Shen Y, et al:
MicroRNA-376c inhibits cell proliferation and invasion in
osteosarcoma by targeting to transforming growth factor-alpha. DNA
Cell Biol. 32:302–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ji F, Zhang H, Wang Y, et al:
MicroRNA-133a, downregulated in osteosarcoma, suppresses
proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.
Bone. 56:220–226. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Townley-Tilson WH, Callis TE and Wang D:
MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac
muscle development, function, and disease. Int J Biochem Cell Biol.
42:1252–1255. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21.
2012.PubMed/NCBI
|
11
|
Namlos HM, Meza-Zepeda LA, Baroy T, et al:
Modulation of the osteosarcoma expression phenotype by microRNAs.
PLoS One. 7:e480862012. View Article : Google Scholar : PubMed/NCBI
|
12
|
Novello C, Pazzaglia L, Cingolani C, et
al: miRNA expression profile in human osteosarcoma: Role of miR-1
and miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013.PubMed/NCBI
|
13
|
Nasser MW, Datta J, Nuovo G, et al:
Down-regulation of micro-RNA-1 (miR-1) in lung cancer: suppression
of tumorigenic property of lung cancer cells and their
sensitization to doxorubicin-induced apoptosis by miR-1. J Biol
Chem. 283:33394–33405. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Datta J, Kutay H, Nasser MW, et al:
Methylation mediated silencing of microRNA-1 gene and its role in
hepatocellular carcinogenesis. Cancer Res. 68:5049–5058. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Leone V, D’Angelo D, Rubio I, et al: MiR-1
is a tumor suppressor in thyroid carcinogenesis targeting CCND2,
CXCR4, and SDF-1alpha. J Clin Endocrinol Metab. 96:E1388–E1398.
2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Wu CD, Kuo YS, Wu HC and Lin CT:
MicroRNA-1 induces apoptosis by targeting prothymosin alpha in
nasopharyngeal carcinoma cells. J Biomed Sci. 18:802011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Napoli C, Sessa M, Infante T and
Casamassimi A: Unraveling framework of the ancestral mediator
complex in human diseases. Biochimie. 94:579–587. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Matsumoto K, Yu S, Jia Y, et al: Critical
role for transcription coactivator peroxisome
proliferator-activated receptor (PPAR)-binding protein/TRAP220 in
liver regeneration and PPARalpha ligand-induced liver tumor
development. J Biol Chem. 282:17053–17060. 2007. View Article : Google Scholar
|
19
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Sarver A, French A, Borralho P, et al:
Human colon cancer profiles show differential microRNA expression
depending on mismatch repair status and are characteristic of
undifferentiated proliferative states. BMC Cancer. 9:4012009.
View Article : Google Scholar
|
21
|
Rao PK, Missiaglia E, Shields L, et al:
Distinct roles for miR-1 and miR-133a in the proliferation and
differentiation of rhabdomyosarcoma cells. FASEB J. 24:3427–3437.
2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Ansari SA and Morse RH: Mechanisms of
mediator complex action in transcriptional activation. Cell Mol
Life Sci. 70:2743–2756. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Collins SR, Miller KM, Maas NL, et al:
Functional dissection of protein complexes involved in yeast
chromosome biology using a genetic interaction map. Nature.
446:806–810. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang H, Jiang H, Wang W, et al:
Expression of Med19 in bladder cancer tissues and its role on
bladder cancer cell growth. Urol Oncol. 30:920–927. 2012.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Yoon NK, Maresh EL, Elshimali Y, et al:
Elevated MED28 expression predicts poor outcome in women with
breast cancer. BMC Cancer. 10:3352010. View Article : Google Scholar : PubMed/NCBI
|
26
|
Schiano C, Rienzo M, Casamassimi A and
Napoli C: Gene expression profile of the whole mediator complex in
human osteosarcoma and normal osteoblasts. Med Oncol. 30:7392013.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Gade P, Singh AK, Roy SK, Reddy SP and
Kalvakolanu DV: Down-regulation of the transcriptional mediator
subunit Med1 contributes to the loss of expression of
metastasis-associated dapk1 in human cancers and cancer cells. Int
J Cancer. 125:1566–1574. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
de Ndong JL, Jean D, Rousselet N and Frade
R: Down-regulation of the expression of RB18A/MED1, a cofactor of
transcription, triggers strong tumorigenic phenotype of human
melanoma cells. Int J Cancer. 124:2597–2606. 2009.PubMed/NCBI
|
29
|
Matsumoto K, Huang J, Viswakarma N, et al:
Transcription coactivator PBP/MED1-deficient hepatocytes are not
susceptible to diethylnitrosamine-induced hepatocarcinogenesis in
the mouse. Carcinogenesis. 31:318–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Vijayvargia R, May MS and Fondell JD: A
coregulatory role for the mediator complex in prostate cancer cell
proliferation and gene expression. Cancer Res. 67:4034–4041. 2007.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Risley MD, Clowes C, Yu M, Mitchell K and
Hentges KE: The mediator complex protein Med31 is required for
embryonic growth and cell proliferation during mammalian
development. Dev Biol. 342:146–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Gao CF and Woude GF: HGF/SF-Met signaling
in tumor progression. Cell Res. 15:49–51. 2005. View Article : Google Scholar : PubMed/NCBI
|